If Brilacidin had successfully met end points the market cap of Ipix would have been around a billion dollars and that would have been just for starters. Now if it still has a chance not only in COVID but many other diseases so I think today’s valuation is way too low but without some believable comments from management we will languish. I am confident though, it won’t be much longer. Giving up on Brilacidin I believe is a big mistake.
News 
Market Data 
Discover 
